Dr. LALIT VERMA

Dr. RITESH NARULA, Dr. AVNINDRA GUPTA

Abstract

Intravitreal Brolucizumab Injection is the newest entrant in the armamentorium of drugs to tackle age related macular degeneration. We share our initial experience of giving 10 Intravitreal brolucizumab injections in 6 eyes ( with 4 eyes having gotten a single injection, 1 eye recieved 2 injections and 1 received 4 injections). Post Injection, all eyes were followed up on day 1, one week & then 4 weeks. None of our patients showed any evidence of vasculitis or signs of intraocular inflammation postoperatively. All the optical coherence tomographs of the patients at 4 week follow up exhibited significant drying effect of the macula with decrease in central macular thickness. Best corrected visual acuity remained nearly stable in all. We attribute no improvement in visual acuity to the presence of previous scarring at the macula as all patients were previously treated with multiple anti-VEGF injections. We, therefore, suggest atleast giving a choice of brolucizumab to patients of Wet AMD not responding to treatment with conventional anti-VEGF treatment.